Chronic Kidney Disease (CKD) affects 15.1% of the world’s population. Approximately 3% of these cases are considered medium to severe (Stage 3 to 5) which is life-threatening and requires immediate clinical treatment. Activated carbon has been developed as a treatment for CKDs by absorbing indole, a precursor of indoxyl sulfate, which is a uremic toxin that, in high levels, contributes to the progression of CKDs. Medications made of high-performance activated carbons have been approved and introduced to the market in Japan, Korea and the Philippines, and is undergoing Phase III evaluation in North America, Latin America and Europe.